Clinical experience to date with nilotinib in gastrointestinal stromal tumors

Seminars in Oncology

Volumn 38, Issue 1 SUPPL., 2011, Pages

  Reichardt, Peter ^a,b   Montemurro, Michael ^c  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b Sarcoma Center   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMATINIB; NILOTINIB; SUNITINIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER PATIENT; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH;

CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79952753171     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.015     Document Type: Article

References (19)

1. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
2. B.J. Druker, S. Tamura, and E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
3. H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052 1056 (Pubitemid 32267975)
4. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626 632 (Pubitemid 351264358)
5. C.D. Blanke, G.D. Demetri, and M. von Mehren Léong-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625 (Pubitemid 351264357)
6. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 2004 1127 1134 (Pubitemid 39296599)
7. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Volume 2. 2010 http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp Accessed August 16, 2010
8. P.G. Casali, and J.Y. Blay Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v98 v102
9. E. Weisberg, P.W. Manley, and W. Breitenstein Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141 (Pubitemid 40248339)
10. P.W. Manley, P. Drueckes, and G. Fendrich Extended kinase profile and properties of the protein kinase inhibitor nilotinib Biochim Biophys Acta 1804 2010 445 453
11. E. Weisberg, R.D. Wright, and J. Jiang Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity Gastroenterology 131 2006 1734 1742 (Pubitemid 44958515)
12. G.D. Demetri, P.G. Casali, and J.Y. Blay A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 15 2009 5910 5916
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2009 2293 2297
15. C. Cauchi, N. Somaiah, and P.F. Engstrom Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S) [abstract 10090] J Clin Oncol 28 15s 2010
16. T. Nishida, A. Sawaki, and T. Doi Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan [abstract 10015] J Clin Oncol 28 15s 2010
17. P. Reichardt, J. Blay, and H. Gelderblom Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3 [abstract 10017] J Clin Oncol 28 15s 2010
18. P.G. Casali, H. Joensuu, and J. Martin Broto Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) [abstract TPS332] J Clin Oncol 28 15s 2010
19. H. Choi Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model Curr Oncol Rep 7 2005 307 311 (Pubitemid 41149677)